Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

Core Insights - The article discusses the impact of positive news on stock prices during meme stock rallies, highlighting the case of Novavax, which saw a 328% increase in stock price after partnering with Sanofi [1]. Group 1: Biotech Stocks in Meme Frenzy - Biotech stocks are favored during meme stock rallies, particularly those in clinical trials, as positive news can significantly boost stock prices [1]. - Atossa Therapeutics (NASDAQ:ATOS) is developing oncology medicines and has a bullish trend with a year-to-date upside of nearly 50%. The company is working on (Z)-endoxifen, which has potential across various breast cancer treatments [3][4]. - Entera Bio (NASDAQ:ENTX) focuses on orally delivered peptide and protein therapeutics, with a 137% stock surge in the last year. Its lead candidate, EB613, targets high-risk post-menopausal osteoporosis, a market affecting 200 million women globally [5][6]. - Actinium Pharmaceuticals (NYSE:ATNM) is developing targeted radiotherapies, with its Iomab-B in phase three trials showing positive data. The company is expected to file for regulatory approval in the second half of 2024 [7]. Group 2: Upcoming Catalysts and Financial Position - Atossa Therapeutics has clinical trial data expected in the second half of 2024, which could lead to a significant stock rally [4]. - Entera Bio is preparing for a Phase three study for EB613, pending FDA qualification of a quantitative BMD endpoint by January 2025, which could act as a catalyst for stock price increase [6]. - Actinium Pharmaceuticals has a solid cash buffer to fund operations into the second half of 2026, indicating no immediate financial concerns [7].